Table 1.
Clinicopathologic characteristics of the patient cohort.
| Patient | Age | BMI | Ethnicity | Tumor Type | Receptor Status | Therapy From Scan 1 to 3 | RECIST by Scan 2 | RECIST by Scan 3 |
|---|---|---|---|---|---|---|---|---|
| 1 | 74 | 18.18 | Hispanic | IDC | (−,−,−) | DC | − | − |
| 2 | 25 | 22.46 | Hispanic | IDC | (−,−,−) | DC | SD | SD |
| 3 | 42 | 24.80 | Hispanic | IDC | (+,−,−) | DC | SD | SD |
| 4 | 47 | 24.80 | Asian | IDC | (+,−,−) | DC | SD | CR |
| 5 | 54 | 24.36 | Caucasian | ILC | (+,+,−) | DC | PD | SD |
| 6 | 59 | 28.30 | Caucasian | IDC | (−,−,−) | PC + I | SD | SD |
| 7 | 63 | 18.95 | Caucasian | IDC | (+,+,−) | DC | − | − |
| 8 | 27 | 18.79 | Caucasian | IDC | (+,+,−) | DC | SD | PR |
| 9 | 32 | 35.8 | Asian | IDC | (+,+,+) | DC* + T | SD | SD |
| 10 | 52 | 21.10 | Caucasian | IDC | (−,−,−) | PC | SD | PR |
| 11 | 38 | 27.50 | Caucasian | IDC | (−,−,−) | PC | SD | PR |
| 12 | 38 | 31.40 | Caucasian | IDC | (−,−,−) | PC + I | PR | PD |
| 13 | 62 | 39.32 | Caucasian | IDC | (−,−,−) | DC | SD | SD |
| 14 | 38 | 36.18 | African American | IDC | (+,+,+) | DC* + T | PR | PR |
| 15 | 42 | 29.95 | Caucasian | IDC | (+,+,−) | DC | SD | SD |
| 16 | 53 | 33.94 | Caucasian | IDC | (+,+,−) | DC | SD | − |
| 17 | 58 | 31.60 | Caucasian | IDC | (−,−,−) | PC + I | PR | PR |
| 18 | 48 | 16.90 | Caucasian | IDC | (+,+,−) | DC | SD | PR |
| 19 | 54 | 26.62 | Caucasian | IDC | (+,+,−) | DC | SD | SD |
| 20 | 41 | 24.21 | Hispanic | IDC | (+,+,+) | DC | PD | PR |
| 21 | 26 | 29.26 | Hispanic | IDC | (−,+,+) | DC | SD | SD |
Bolded labels denote changes in the RECIST category from the scan 1 to scan 2 evaluation to the scan 1 to scan 3 evaluation. Patients 6, 9, and 14 did not receive a second regimen; therefore, for patients 6 and 9, scans 2–4 were acquired after the first through third cycles, respectively, and for patient 14, scan 2 was acquired after the first cycle, scan 3 after the fourth, and scan 4 after the fifth. Three patients (6, 12, and 17) received either the active pembrolizumab drug or the placebo in addition to chemotherapy (NCT03036488). Bolded patients are chemo subgroup patients used for the in silico therapy regimen study.
BMI = body mass index; CR = complete response; DC = doxorubicin and cyclophosphamide; DC* = docetaxel and carboplatin; ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; +I = immunotherapy regimen (pembrolizumab or placebo); IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; P = paclitaxel; PC = paclitaxel and carboplatin; PD = progressive disease; PR = progesterone receptor; PR = partial response (RECIST); +T = targeted therapies trastuzumab and pertuzumab; SD = stable disease.